Cervical cancer is the third most common cancer in women worldwide (1) . Persistent infection with oncogenic types of human papillomavirus (HPV) is the main cause of cervical cancer and its precursor lesions, cervical intraepithelial neoplasia where cervical intraepithelial neoplasia III is considered the same as carcinoma in situ (CIS) or stage 0 cervical cancer (2) . HPV infections are common, but only a small fraction of infected women develop cervical cancer (3) . Cervical carcinoma displays sizable familial aggregation at a magnitude similar to that seen for several other cancers (4) . Moreover, the pattern of increasing familial relative risk with increasing degree of biological relatedness supports the notion that genetic factors are a major cause of the familial aggregation in cervical cancer (5) . However, our understanding of the genetic basis of cervical cancer is still limited. Research on cervical cancer susceptibility has focused mainly on the human leukocyte antigen (HLA) genes, which encode molecules that present antigens to the immune system. The most consistent findings have been for DRB1*1501-DQB1*0602 and DRB1*1301-DQB1*0603, which are associated with increased and decreased risk of cervical cancer, respectively (6) (7) (8) (9) (10) (11) . To further elucidate the genetic basis of cervical cancer, we conducted a genome-wide association study (GWAS) of cervical cancer in the Swedish population.
Methods

Study Populations
The studies included are described briefly in Supplementary  Table 1 (available online) . Subjects included in the discovery phase are from two studies, the CervixCan I study and the TwinGene study. In the CervixCan study, cervical cancer case subjects were selected from families with at least two affected women from Sweden who were born after 1940 and reported to the Swedish Cancer Registry before 1993. All case subjects were from the Swedish population. Details on study designs and subjects recruitment have been described previously (11) . The CervixCan study was further divided into two parts (ie, the CervixCan I study that is comprised of case subjects who are the sole participants of their family and CervixCan II study that is comprised of individuals with more than one first-degree relative also participating). Seven hundred sixty-six sole participants (720 CIS and 46 invasive carcinoma) from the CervixCan I study were included in the discovery phase. The TwinGene study is a population-based Swedish study of twins born between 1911 and 1958. In total, 9896 subjects were genotyped consecutively with those from the CervixCan I study using Illumina HumanOmniExpress BeadChip (Illumina, San Diego, CA) (731 422 single-nucleotide polymorphisms [SNPs] ). All the subjects included were of self-reported Swedish ethnicity. Among these subjects, 309 unrelated cervical cancer cases (288 CIS and 21 invasive carcinoma) were further included in the discovery phase. One female singleton was then randomly selected from each twin pair without cervical cancer, resulting in 4014 unrelated cervical cancer-free women who were included as control subjects. The subjects used in the discovery phase of this study have not been included in any of our previous studies (11, 12) .
The replication series was comprised of 1140 case subjects diagnosed with cervical tumors (1104 CIS and 36 invasive carcinoma) from the CervixCan II study. Briefly, the case subject sample included 942 individuals with one first-degree relative (mother, sister, or daughter) and 39 case subjects with two first-degree relatives also participating in the study as well as 159 individuals with no participating family member. One thousand fifty-eight control subjects (485 women and 573 men) were collected among unrelated blood donors at Uppsala University Hospital and were of Swedish descent. Informed consent was obtained from all subjects, and each study was approved by the regional ethical review board in Uppsala.
Quality Control in the GWAS
Systematic quality control steps were conducted on the raw genotyping data (Supplementary Table 2 , available online). The exclusion criteria for SNPs were minor allele frequency less than or equal to 1%, genotyping call rate less than 99%, genotype frequency that deviated from Hardy-Weinberg equilibrium among control subjects (P < 1 × 10 −7 ), and a statistically significant difference in missing rate between case subjects and control subjects (P < 1 × 10 −7
). Individuals with overall genotyping rate less than 95% were excluded. Samples were excluded if heterozygosity rates for autosomal chromosomes were greater than six standard deviations from the mean. We also conducted further exclusions for those with abnormal heterozygosity rate on the X chromosome. Unexpected duplicates and first-degree and second-degree relatives were removed based on identity-bystate estimates calculated in PLINK (13) . Using a set of 17 386 SNPs evenly distributed across the genome and in low linkage disequilibrium (LD) (pairwise r 2 < 0.02) that passed quality control, a two-step procedure was used to identify non-European outliers. In the first step, STRUCTURE analysis (14) was performed by including the founders of the HapMap trios of CEU (Utah residents with Northern and Western European ancestry), YRI (Yoruba in Ibadan, Nigeria), CHB (Han Chinese in Beijing), and JPT (Japanese in Tokyo) as the internal controls (Supplementary Figure 1 , available online). Seven samples with less than 80% CEU ancestry were excluded at this step.
In the second step, a principal components analysis without HapMap samples using EIGENSTRAT (15) excluded five additional outliers that exceeded six standard deviations from the mean along any of the top 10 principal components (PCs) (Supplementary Figure 2 , available online).
Independent Replication
To validate the findings from the whole-genome scan, three independent SNPs identified by direct genotyping (rs9272143, rs2516448, rs3117027) and two SNPs identified by imputation (rs1882 and rs9271720) were genotyped in the replication study. rs2516448 was genotyped using the TaqMan assay (Applied Biosystems, Foster City, CA) and the others were genotyped with the GeniosPro platform (Tecan, Männedorf, Switzerland). Seven percent of the samples were selected for repeat genotyping as duplicates, yielding a reproducibility of 100%. Genotype success rate was greater than 97.3%.
Statistical Analysis
The association between each genetic variant and disease risk was estimated by the odds ratio (OR) and 95% confidence interval (CI) using multivariable unconditional logistic regression assuming a log-additive genetic model as the primary analysis of the discovery phase. Nine eigenvectors were identified based on the TracyWidom statistic (P <.05) from the principal components analysis. Adjustment for population stratification was performed by including these eigenvectors as covariables in the logistic regression.
Stepwise conditional analysis was conducted to interrogate associated regions for independent secondary signals. The association between top SNPs and cervical cancer was further estimated by odds ratios and 95% confidence interval per allele (minor allele vs major allele) and per genotype derived from unconditional logistic regression.
In the replication study, to account for correlation between related subjects, the association analysis was performed using PedGenie (16) , which allows for a mixture of pedigree members and independent individuals to be analyzed together. Empirical 95% confidence intervals and P values were calculated using 100 000 000 simulations. The inflation caused by relatedness is relatively small (data not shown). Results of the genome-wide and independent replication analyses were combined with metaanalysis applying the inverse variance weighting method (17) . Between-study heterogeneity in effect was evaluated using the Cochran Q test statistic. Results that obtained P less than 5.0 × 10 −8 were considered statistically significant at the genome-wide level. All statistical tests were two-sided. Unless specified, odds ratios and P values from allelic tests are presented for the top SNPs when describing the discovery and replication results. All analyses were conducted using PLINK (13) and SAS 9.3 software (SAS Institute, Cary, NC).
results
After stringent quality control, data from 1034 case subjects and 3948 control subjects were available for 632 668 SNPs with an overall call rate of 99.92%. The quantile-quantile plot shows minimal evidence of genomic inflation (λ= 1.031) (Supplementary Figure 3 , available online). Adjustment for the informative eigenvectors indicated that population stratification was unlikely to account for the identified associations reported below (Supplementary Table 3 , available online).
When testing each SNP individually, 55 SNPs were associated with cervical cancer with a P value less than 5 × 10 −8 in the log-additive model (Supplementary Table 4 , available online). All 55 SNPs are located within the major histocompatibility complex (MHC) region at 6p21.3 ( Figure 1 ). The strongest signal of association comes from rs9272143 located between HLA-DRB1 and HLA-DQA1 (OR = 0.65, 95% CI = 0.59 to 0.72; P = 2.8 × 10
−17 in allelic test) ( Figure 1 ; Table 1 ). When conditioning upon rs9272143, residual association was detected at some SNPs in this region, with the most statistically significant signal occurring at rs2516448 adjacent to the MHC class I polypeptide-related sequence A gene (MICA) (OR = 1.46, 95% CI = 1.32 to 1.61, P = 8.6 × 10 −14 compared with OR = 1.44, 95% CI = 1.30 to 1.58, P = 5.8 × 10 −13 for the unconditional analysis in allelic test). Further conditioning on rs2516448 still left residual association at rs3117027, which is located within the pseudogene HLA-DPB2 (OR = 1.27, 95% CI = 1.14 to 1.41, P = 7.0 × 10 −6 compared with OR = 1.28, 95% CI = 1.15 to 1.42, P = 3.1 × 10 −6 for the unconditional analysis in allelic test) ( Table 1 ). The LD between these three SNPs is very weak (pairwise r 2 = 0.001), consistent with three independently acting loci. Conditioning on all three SNPs jointly left little evidence for residual association at 6p21.3. Because rs3117027 maps closely to HLA-DPB1, which has been implicated in cervical cancer susceptibility (12) , it was included in the replication stage in addition to rs9272143 and rs2516448. The association of rs2516448, rs9272143, and rs3117027 was consistently replicated in an independent set of 1140 cervical cancer case subjects and 1058 control subjects, with no evidence of heterogeneity between studies. In allelic tests in the combined analysis, the risks for cervical cancer associated with the three loci were as follows: rs2516448 (OR = 1.42, 95% CI = 1.31 to 1.54, P = 1.6 × 10 association with these three SNPs was noted by tumor stage (CIS vs invasive carcinoma), although the number of case subjects with invasive cancer was limited (Figure 2) .
The MHC region is characterized by a complex LD pattern that extends across multiple HLA and non-HLA genes (18) . In the imputed data of classic HLA alleles (see Supplementary Methods, available online), one HLA class I allele (B*0702) and five class II alleles (DRB1*1301, DRB1*1501, DQA1*0103, DQB1*0603, and DQB1*0602) showed evidence of association with cervical cancer at the P equal to 5 × 10 −7 threshold (Supplementary Table 5 , available online), consistent with commonly reported HLA associations with cervical cancer in European populations (6) (7) (8) (9) (10) (11) 19 Table 6 , available online), suggesting that the imputed HLA data is reliable. When conditioning on B*0702, DRB1*1301-DQA1*0103-DQB1*0603, or DRB1*1501-DQB1*0602, similar strength of association was observed for rs2516448, rs9272143, and rs3117027, as compared with unconditional analysis. Comparable results were also observed in subgroups negative for these HLA allele/haplotypes, consistent with the effects of the top SNPs being independent from the above HLA alleles/haplotypes (Table 3) .
SNP imputation across the MHC region based on the 1000 Genomes Project (20) (Supplementary Methods, available online) revealed that the most strongly associated variants in the class I region are confined to the MICA gene, including a nonsynonymous variant rs1882 (OR = 0.70, 95% CI = 0.63 to 0.77, P = 1.4 × 10 −12 ). A group of highly correlated variants tagged by rs9271720 in the class II region showed a stronger effect than rs9272143 (rs9271720; OR = 0.63, 95% CI = 0.56 to 0.70, P = 3.3 × 10 −18 ) (Supplementary Figure 4 , available online). The concordance between imputed and direct genotyping data was 98.1% for rs1882 and 89.1% for rs9271720 (see Supplementary Methods, available online). A comparable association was noted for rs1882 but not for rs9271720 in the replication study (P heterogeneity = 0.38 and 8.0 × 10 −3 between discovery and replication phase, respectively) (Supplementary Table 7 , available online). Conditional analysis on rs2516448 resulted in substantial attenuation of the association with rs1882 in both discovery and replication phases (data not shown), suggesting that the effect of rs1882 is due to LD with rs2516448.
SNP rs2516448 resides adjacent to MICA, which encodes a membrane-bound protein acting as a ligand for the NKG2D activating immunoreceptor (21) . Its transmembrane domain (TMD) contains a triplet repeat microsatellite polymorphism consisting of four, five, six, or nine repetitions of GCT (alleles designated A4, A5, A6, or A9, respectively) or five repetitions Table 4 ). The loss of 52 amino acids and lower content of hydrophobic amino acids of the MICA protein encoded by the A5.1 allele is likely to negatively affect its ability to be stably expressed on the membrane. We therefore examined whether the A5.1 allele had an effect on the amount of membranebound MICA using immunohistochemistry (Supplementary Methods, available online) on cervical tumor tissue samples from the CervixCan study (249 CIS and 13 cervical squamous cell carcinoma). Notably, the A5.1 allele was significantly associated with less membrane-bound MICA (P =.02), and specifically, the odds of being negative for membrane-bound MICA for carriers of the A5.1/A5.1 genotype was 3.24-fold greater than that for noncarriers (P =.03) ( Table 5 ; Figure 3 ).
Discussion
We have performed the first GWAS of cervical cancer and identified three independently acting loci within the MHC region; rs2516448 (class I region in proximity to MICA), rs9272143 (class II region between HLA-DRB1 and HLA-DQA1) and rs3117027 (class II region at HLA-DPB2). Furthermore, we confirmed previously reported associations of B*0702, DRB1*1501-DQB1*0602, and DRB1*1301-DQA1*0103-DQB1*0603 with cervical cancer (6) (7) (8) (9) (10) (11) 19) . However, the three new loci are statistically independent of these specific HLA alleles/haplotypes. The risk allele of rs2516448 in the first locus is in perfect LD with A5.1, a frameshift mutation of MICA. This membrane-bound protein is absent from most cells but can be induced by viral infections and is frequently expressed in epithelial tumors (23) . Upon binding to MICA, NKG2D activates cytolytic responses of gamma/delta T cells and natural killer cells against transfectants and tumor cells expressing MICA (21) . Therefore, membrane-bound MICA acts as a signal during the early immune response against infection or spontaneously arising tumors. On the other hand, human tumor cells spontaneously release a soluble form of MICA by cleavage at the TMD, causing severe impairment of the responsiveness of tumor antigen-specific effector T cells. This is considered to promote tumor immune evasion and also to compromise host resistance to infections (23, 24) . High levels of the soluble form of MICA have been detected in sera of patients with malignancy and those with chronic infection, including cervical cancer and precursor lesions, but not in healthy subjects (25, 26) . The MICA protein encoded by the A5.1 allele is aberrantly transported to a nonphysiological location in epithelial cells (27) , which may result in an easier release to the serum. A number of reports have shown association between the A5.1 allele and higher level of the soluble form of MICA (28) (29) (30) . By immunohistochemistry, we showed that cervical neoplasia patients carrying the A5.1 allele have less membrane-found MICA in their lesions, which may compromise their ability to alert the immune system of HPV infection or neoplastic change, leading to impaired immune activation and increased risk of tumor development. The MICA-A5.1 variant has previously been associated with autoimmune diseases and several types of cancer (28) (29) (30) (31) (32) , supporting its role in immune response and tumor development. A previous study has reported an association of cervical cancer with the same microsatellite in the MICA gene, but because of differences in the primers used in the typing between the studies, it was impossible to discern if the same allele is responsible for the association (33). Association between three independent loci and cervical cancer in the combined series. Unless specified, association results of the genome-wide and independent replication analyses were combined with meta-analysis applying the inverse variance weighting method for each stratum. P for heterogeneity (P het ) was derived from the Cochran Q test. * Derived from logistic regression model for the minor allele compared to the major allele with adjustment for the nine informative eigenvectors. † Empirical 95% confidence intervals (CI) and P values were calculated for the minor allele compared with the major allele from 100 000 000 simulations in PedGenie to correct for the genetic dependence of related individuals. Ca = case subject; Co = control subject; GWAS = genome-wide association study; OR = odds ratio.
JNCI | Articles 629 jnci.oxfordjournals.org . * P values are two-sided and correspond to the odds ratio. GWAS = genome-wide association study; CI = confidence interval; OR = odds ratio; SNP, single nucleotide polymorphism. † Derived from logistic regression model with adjustment for the nine informative eigenvectors generated by principal components analysis. ‡ Empirical 95% confidence intervals and P values were calculated from 100 000 000 simulations in PedGenie to correct for the genetic dependence of related individuals. § Between-study heterogeneity effect was evaluated using the Cochran Q test statistic.
|| Results of the genome-wide and independent replication analyses were combined with meta-analysis applying the inverse variance weighting method. ¶ Number of case subjects and control subjects, respectively.
The top SNP (rs9272143) in the second locus is located within an intergenic region containing no obvious functional elements. However, it resides adjacent to the hypervariable HLA-DRB locus, which has haplotype-specific gene copy number variations between the HLA-DRB9 pseudogene and HLA-DRB1, where HLA class II haplotypes carry zero or one additional functional DRB gene (HLA-DRB3, -DRB4, or -DRB5) (34) . To test whether the association with rs9272143 is because of its LD with a second expressed DRB gene, the presence of HLA-DRB3, -DRB4, and -DRB5 was inferred from HLA-DRB1 allelic data (Supplementary Methods, available online). In the discovery phase, the HLA-DRB3-carrying haplotype was associated with decreased risk of cervical cancer (OR = 0.66, 95% CI = 0.59 to 0.74, P = 3.0 × 10 −13 ), whereas the haplotype carrying HLA-DRB4 or HLA-DRB5 was associated with increased risk (OR = 1.32, 95% CI = 1.17 to 1.50, P = 9.1 × 10 −6 ; and OR = 1.36, 95% CI = 1.20 to 1.54, P = 1.3 × 10 -6 , respectively) (Supplementary Table 8 , available online). However, the association with rs9272143 was little altered upon conditioning on haplotypes carrying additional DRB genes, consistent with none of them explaining this association (Supplementary Table 9 , available online). Further studies are needed to determine the nature of the functional effect of rs9272143 on cervical cancer risk.
The third locus, marked by rs3117027, maps closely to HLA-DPB1, which encodes the β-chain of the peptide-antigen receptor HLA-DP. The alleles at HLA-DPB1 were not possible to impute because of lack of training data, but direct HLA-DPB1 typing data shows a correlation between rs3117027 and DPB1*0301 (D'= 0.79; r 2 = 0.20) (Supplementary Table 6 , available online), which has been found to be associated with increased risk of cervical cancer (12) as well as chronic hepatitis B, Hodgkin's disease, and type 1 diabetes (35) (36) (37) . It remains to be clarified whether the association with rs3117027 is driven by DPB1*0301. Some limitations in our study should be noted. First, most of the cervical cancer cases included were CIS and only 4.5% were invasive squamous cell carcinoma. We therefore had higher power to detect variants associated with CIS and only limited power to identify associations with invasive carcinoma. Although the susceptibility loci showed homogeneous effects by tumor stage, the power to detect heterogeneity was limited, given the small sample size of invasive cancer. Second, our study did not include case subjects with adenocarcinomas or information on HPV type. Hence, we are not able to assess whether the discovered SNPs affect the susceptibility to adenocarcinomas or if the effect is specific for certain HPV types.
In summary, we performed the first GWAS of cervical cancer and identified three novel and independent loci within the MHC region contributing to the risk of developing cervical cancer, in addition to previously known associations with classic HLA loci. In particular, the MICA-A5.1 variant results in less membrane-bound MICA. This may affect immune activation and immune surveillance against HPV-infected cells, increasing the risk of cervical cancer development. It is worth noting that the MICA-A5.1 variant is quite common in many populations (38) , with a frequency of up to 59% in the cervical cancer patients in our study. Our results apply to CIS, which represent the vast majority of cases, and progression to invasive cancer may require additional, as yet unknown, risk factors. However, CIS and invasive cancer share the same main etiological factor, namely persistent infection by oncogenic types of HPV, indicating that the genetic susceptibility loci identified for CIS will have a similar effect on the two cancer stages. Information on the MICA genotype may be useful for stratifying women with invasive cervical cancer on alternative therapies based on their inherent capacity to activate an antitumor response. For instance, epirubicin therapy has been found to activate antitumor immunity through inhibition of MICA shedding in hepatocellular carcinoma (39) , and cervical cancer patients who received epirubicin and radiation therapy showed longer disease-free and cumulative survival compared with radiotherapy alone in a randomized trial (40) . Future studies are warranted to determine whether the MICA-A5.1 variant can modify the efficiency of epirubicin in cervical cancer patients. * All the analysis was performed based on phased data. Unless specified, odds ratios (ORs) and 95% confidence itnervals (CIs) for minor allele compared with major allele of each single nucleotide polymorphism were derived from logistic regression with adjustment for the nine informative eigenvectors. For conditional analysis, specified human leukocyte antigen allele/haplotypes were further included as covariables in the logistic regression. P values are two-sided and correspond to the odds ratio. * CI = confidence interval; LD = linkage disequilibrium; OR = odds ratio. † Estimated in all the 1140 case subjects from 641 families. ‡ Estimated in 641 randomly selected singletons stemming from each family by Haploview. § The reference group is all individuals who do not carry each of the microsatellite alleles. Empirical 95% confidence intervals and P values were calculated using PedGenie with 100 000 000 simulations to correct for the genetic dependence of related cases.
The loci associated with increased risk of CIS are all located in the MHC region, indicating that the main host genetic susceptibility factors to cervical cancer are related to the immune recognition of HPV-infected or -transformed cervical epithelial cells. Such a strong effect of the MHC region is commonly seen in GWASs of disorders with an autoimmune or inflammatory etiology. Further studies, using larger sample size and new approaches, such as genome-wide sequence-based association analysis, are needed to define more fully the inherited basis of cervical cancer. Also, such studies may address the contribution of structural variation, such as that found in the HLA-DRB region, to cervical cancer susceptibility. * CI = confidence interval; OR = odds ratio. † The association between A5.1 genotypes and being negative for membranebound MICA was estimated using logistic regression model. ‡ The association between the A5.1 allele and being negative for membranebound MICA was estimated using logistic regression assuming log-additive genetic model. § Tumor stage and age of diagnosis are not associated with membrane-bound MICA status and hence not included in the model as covariabes.
